Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Milford, Connecticut Clinical Trials

A listing of Milford, Connecticut clinical trials actively recruiting patient volunteers.

RESULTS

Found (54) clinical trials

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Phase

6.7 miles

Learn More »

A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.

Phase

6.7 miles

Learn More »

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

To study the effects of ethanol clamped at BAC 0.04% and THC (1.05 mg in a 70 kg individual) on driving.

Phase

6.7 miles

Learn More »

The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)

150 cocaine dependent individuals will be randomly assigned to one of 3 conditions delivered over 4 weeks in the context of intensive outpatient treatment. 1. Treatment as Usual (TAU), 2. rapid abstinence initiation (RAI) or 3. computerized cognitive control training with escalating reinforcement for improved performance on training tasks (CCT). ...

Phase

7.41 miles

Learn More »

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI3726 in subjects with mCRPC who have received prior treatment with ...

Phase

8.16 miles

Learn More »

A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies

The study will be conducted in two segments. The first segment of the study (Phase 1a) will be a dose escalation design in order to determine the Maximum Tolerated Dose (MTD) of AZD4635 given as monotherapy and in combination with durvalumab. The MTD will be determined by assessing adverse events ...

Phase

8.16 miles

Learn More »

Efficacy of Psilocybin in OCD: a Double-Blind Placebo-Controlled Study.

Aim 1: To investigate the effects of psilocybin on OCD symptomatology. OCD symptom severity will be assessed before treatment and 24 and 48 hours after treatment, one week after treatment, two weeks, one month, three months, and six months after treatment. Hypothesis: We hypothesize that 0.25mg/kg of psilocybin will lead ...

Phase

8.16 miles

Learn More »

Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS

This study is designed to look at the relationship between brain glucose utilization, neurotransmission (e.g., glutamate, also known as the main excitatory amino-acid neurotransmitter in the brain), and synaptic density. This relationship will be explored in the brain's prefrontal cortex, an area important in decision-making and impulsivity.

Phase

8.16 miles

Learn More »

A Study of Obinutuzumab Rituximab Polatuzumab Vedotin and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab vedotin, and venetoclax in participants with DLBCL. Participants with FL who achieve complete response (CR), partial response (PR), or stable disease ...

Phase

8.9 miles

Learn More »

Study Evaluating the Safety Pharmacokinetics (PK) Pharmacodynamics (PD) and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in ...

Phase

8.9 miles

Learn More »